drugset / Trial / NCT00857233

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857233

Phase 3 Terminated 297 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.

Timeline

Start
2004-06
Primary completion
2010-07
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg Oral

Indications